Skip to Content

Iclaprim Approval Status

Iclaprim is an investigational broad-spectrum diaminopyrimidine antibiotic in development for the treatment of acute bacterial skin and skin structure infections (ABSSSIs).

Development Status and FDA Approval Process for iclaprim

DateArticle
Mar  2, 2016First Patient Dosed in Iclaprim Phase 3 Trials to Treat Skin Infections
Sep  3, 2015FDA Grants Fast Track Designation for Iclaprim
Jul 22, 2015FDA QIDP Designation for Motif’s Lead Antibiotic Candidate Iclaprim for ABSSSI
Jan 20, 2009FDA Issues Complete Response Letter for Iclaprim
Nov 21, 2008Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome
Oct 14, 2008Arpida Announces Review of Iclaprim NDA by FDA Advisory Committee in November 2008
May 16, 2008Arpida Announces FDA Acceptance of the Iclaprim New Drug Application
Mar 19, 2008Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide